Wednesday, October 03, 2018 2:36:56 PM
I'm sorry but I can't take any of that seriously. There were no buyout talks. The best we could have hoped for was continuation of the collaboration and the start of two phase 3 trials and maybe expansion of the program into combo trials. Instead they decided it wasn't worth it and discontinued the collaboration entirely. It's as simple as that.
I'm just saying that it's difficult for me to believe that they made this decision some time in the week between the 13th, when they told everyone that imetelstat was still one of their prospective drugs, and the 26th, when they told Geron the news. Maybe I'm wrong in saying that it was deception on their part and it's all just badly handled PR, but there was too much money involved for me to totally believe that there was no deception whatsoever.
I'm just saying that it's difficult for me to believe that they made this decision some time in the week between the 13th, when they told everyone that imetelstat was still one of their prospective drugs, and the 26th, when they told Geron the news. Maybe I'm wrong in saying that it was deception on their part and it's all just badly handled PR, but there was too much money involved for me to totally believe that there was no deception whatsoever.
Recent GERN News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 08:01:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 11:45:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 11:45:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 11:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 11:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 11:45:05 PM
- Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/18/2026 08:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 12:40:51 PM
- First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 • GlobeNewswire Inc. • 05/12/2026 01:31:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:49:33 PM
- Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Geron Plans to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/05/2026 12:00:00 PM
- Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026 • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/20/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/15/2026 12:14:14 AM
- Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/14/2026 08:05:00 PM
- Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary • GlobeNewswire Inc. • 04/13/2026 12:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/07/2026 08:31:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/07/2026 08:30:34 PM
- Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/06/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 08:30:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 09:37:09 PM
